News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Ambrilia Biopharma Inc. Reports Issuance Of U.S. Patent On PCK3145, Its Lead Drug Candidate For Advanced Metastatic Prostate Cancer
May 30, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
U.S. Patent No. 7053058 covers the Signal Transduction Inhibitor PCK3145 and related sequences.
Twitter
LinkedIn
Facebook
Email
Print